-
Evaxion Biotech Partners With Merck To Expand Vaccine Development
Thursday, September 26, 2024 - 10:53am | 376Read More...Evaxion Biotech A/S (NASDAQ:EVAX) inked an option and licensing deal with Merck & Co., Inc (NYSE:MRK) for two preclinical vaccine candidates. Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 and EVX-B3. EVX-B2 is a protein-based candidate for Gonorrhea, and...
-
'Biggest Invention Since Lateral Flow': Gemina Labs CEO Touts Company's Transformative Diagnostics Deal
Friday, June 21, 2024 - 3:11pm | 512Read More...At the Benzinga Healthcare & Biotech Breakthroughs virtual event Thursday, Brian Firth, CEO of Gemina Labs, spoke about the company’s agreement with a major global diagnostics firm, marking a notable step forward for the Canadian-based company. This deal will enhance the performance of...
-
Health Care, Biotech Leaders To Unveil Cutting-Edge Innovations
Monday, June 17, 2024 - 2:01pm | 355Read More...On Thursday at 11 a.m. EST, Benzinga will host a Healthcare & Biotech Breakthroughs virtual conference. This online event will bring together industry leaders to discuss recent advancements in healthcare and biotechnology that are transforming patient care and creating new investment avenues....
-
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
Tuesday, May 21, 2024 - 10:41pm | 635Read More...The Structure Therapeutics (NASDAQ:GPCR) stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. What Happened: JPMorgan has initiated coverage of Structure Therapeutics, a biotech company, with an “Overweight...
-
US Intelligence Claims Chinese Pharma Giant Illegally Shared Secrets With Beijing
Thursday, March 28, 2024 - 3:13am | 670Read More...U.S. intelligence officials have informed senators that WuXi AppTec Co Ltd (OTC:WXIBF), a Chinese pharmaceutical company, allegedly transferred U.S. intellectual property to Beijing without authorization. This news comes amid concerns that certain Chinese biotech firms are providing technology or...
-
Nvidia, Boeing, Ardelyx, Crocs, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Monday, January 8, 2024 - 11:39pm | 1240Read More...On Monday, U.S. indices ended the trading day in the green with the Nasdaq gaining 2.2% to 14,843.77. The S&P 500 rose 1.14% to 4,763.54 while the Dow Jones index appreciated nearly 0.6% to 37,683.01. These are the top stocks that gained the attention of retail traders and investors throughout...
-
These Biotech Stocks Could Double Your Money, According To Analysts
Thursday, November 9, 2023 - 10:38am | 932Read More...The biotech industry has been in the limelight since the COVID-19 pandemic, with public and private sectors pouring in funds to bolster innovation and the development of relevant drugs. Approximately 63% of public biotech firms reported revenue growth in 2021. Emerging biotech companies,...
-
Elon Musk Questioned By Ethics Group Over Painful Deaths Of Monkeys Linked To Neuralink
Thursday, September 21, 2023 - 10:04am | 590Read More...Elon Musk is facing another round of allegations of securities fraud, and this time, it comes from a medical ethics group questioning Musk's statement on the death of monkeys at his biotech startup Neuralink. What Happened: Even as Musk claimed that no monkeys died due to Neuralink implants, a new...
-
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
Friday, September 8, 2023 - 8:42am | 1781Read More...Swedish biopharma Calliditas Therapeutics AB (NASDAQ:CALT) is making significant strides in addressing rare kidney diseases. In a recent interview with Benzinga, the company’s CEO, Renee Aguiar-Lucander, provided valuable insights on various aspects of its work. Tarpeyo – A Unique...
-
The Secret Behind Why Your Coffee and CBD Might Not Be Working
Wednesday, August 9, 2023 - 6:06pm | 897Read More...Rexis Biotech is dedicated to enhancing the health and well-being of people by manufacturing and distributing high-quality, delicious consumables nationwide. Many find themselves consuming way too much caffeine when the caffeine intake isn’t the issue. Rexis Biotech is looking to solve this....
-
J&J Investors Will Soon Be Able To Exchange Shares For Kenvue Stocks
Friday, July 21, 2023 - 1:54am | 446Read More...Shareholders of Johnson & Johnson (NYSE:JNJ) will soon have the opportunity to exchange their shares for those of Kenvue Inc. (NYSE:KVUE), the consumer health company that spun off from J&J two months ago, CNBC reports. What Happened: J&J, which owns nearly 90% of Kenvue shares, plans...
-
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
Tuesday, June 20, 2023 - 5:14pm | 811Read More...In a recent report, Bank of America identified the “Disruptive Dozen” emerging technologies that have the most potential to disrupt and revolutionize the healthcare sector over the next years. New therapy for ALS (amyotrophic lateral sclerosis) and a blood test for Alzheimer’s...
-
11 Biotech Stocks Moving From ASH 2017
Monday, December 11, 2017 - 5:24pm | 1170Read More...The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited incremental reaction, with the direction and magnitude of the moves dependent on the market...
-
It's A Bad Day For Biotechs
Thursday, October 26, 2017 - 10:30am | 398Read More...Biotech stocks are off to a rough start on Thursday, especially Celgene Corporation (NASDAQ: CELG), as shares plummeted to a new 52-week low of $95.50. Celgene reported Wednesday mixed third-quarter results, but investors appear to be fixated on the company's 2020 guidance update. The company...
-
Pro: Biotech Is The Hottest ETF Of 2017 With Plenty Of Upside Ahead
Thursday, September 7, 2017 - 9:38am | 460Read More...The single hottest large-cap exchange-traded fund, the SPDR S&P Biotech (ETF) (NYSE: XBI), is up more than 40 percent since the start of 2017 and by 10 percent in the past two weeks alone. Many investors aren't willing to assume the inherent risk that comes with investing in highly volatile...
















